Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1865-8652
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan ; day:24 ; month:1 ; year:2023 ; pages:1-20
Advances in therapy ; (24.1.2023), 1-20

Urheber
Ogura, Takashi
Inoue, Yoshikazu
Azuma, Arata
Homma, Sakae
Kondoh, Yasuhiro
Tanaka, Katsumi
Ochiai, Kaori
Sugiyama, Yukihiko
Nukiwa, Toshihiro
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s12325-022-02411-y
URN
urn:nbn:de:101:1-2023033122130428845214
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:03 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Ogura, Takashi
  • Inoue, Yoshikazu
  • Azuma, Arata
  • Homma, Sakae
  • Kondoh, Yasuhiro
  • Tanaka, Katsumi
  • Ochiai, Kaori
  • Sugiyama, Yukihiko
  • Nukiwa, Toshihiro
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

Verbundene Objekte